

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number  
**WO 02/059280 A2**(51) International Patent Classification<sup>7</sup>: **C12N 5/08**,  
C07K 16/30, G01N 33/577 // C12N 15/10

(21) International Application Number: PCT/US01/47931


(22) International Filing Date:  
10 December 2001 (10.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/254,113 8 December 2000 (08.12.2000) US(71) Applicant (for all designated States except US): **ALEX-  
ION PHARMACEUTICALS, INC.** [US/US]; 352 Knot-  
ter Drive, Cheshire, CT 06410 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).**Published:**— without international search report and to be republished  
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(72) Inventors; and  
(75) Inventors/Applicants (for US only): **BOWDISH,**  
Katherine, S. [US/US]; 13754 Boquita Drive, Del Mar,  
CA 92014 (US). **MCWHIRTER, John** [US/US]; 9499  
Questa Pointe, San Diego, CA 92126 (US).(74) Agents: **DELUCA, Peter** et al.; Dilworth & Barrese, LLP,  
333 Earle Ovington Boulevard, Uniondale, NY 11553  
(US).

(54) Title: CHRONIC LYMPHOCYTIC LEUKEMIA CELL LINE

**CELL ELISA**

WO 02/059280 A2

(57) Abstract: A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed.

## **CHRONIC LYMPHOCYTIC LEUKEMIA CELL LINE**

### **RELATED APPLICATIONS**

This application claims priority to U. S. Provisional Application No. 60/254,113 filed December 8, 2000, the disclosure of which is incorporated herein by reference.

### **TECHNICAL FIELD**

5 Cell lines derived from chronic lymphocytic leukemia (CLL) cells and the uses thereof in the study and treatment of CLL disease are disclosed. In particular, this disclosure relates to a CLL cell line designated "CLL-AAT", deposited on November 28, 2001 with the American Type Culture Collection (Manassas, Virginia, USA) in accordance with the terms of the Budapest Treaty under ATCC accession no. XXXXX.

### 10 **BACKGROUND**

Chronic Lymphocytic Leukemia (CLL) is a disease of the white blood cells and is the most common form of leukemia in the Western Hemisphere. CLL represents a diverse group of diseases relating to the growth of malignant lymphocytes that grow slowly but have an extended life span. CLL is classified in various categories that  
15 include, for example, B-cell chronic lymphocytic leukemia (B-CLL) of classical and mixed types, B-cell and T -cell prolymphocytic leukemia, hairy cell leukemia, and large granular lymphocytic leukemia.

Of all the different types of CLL, B-CLL accounts for approximately 30 percent of all leukemias. Although it occurs more frequently in individuals over 50 years of age  
20 it is increasingly seen in younger people. B-CLL is characterized by accumulation of B-lymphocytes that are morphologically normal but biologically immature, leading to a loss of function. Lymphocytes normally function to fight infection. In B-CLL, however, lymphocytes accumulate in the blood and bone marrow and cause swelling of the lymph nodes. The production of normal bone marrow and blood cells is reduced and  
25 patients often experience severe anemia as well as low platelet counts. This can pose

the risk of life-threatening bleeding and the development of serious infections because of reduced numbers of white blood cells.

To further understand diseases such as leukemia it is important to have suitable cell lines that can be used as tools for research on their etiology, pathogenesis and biology. Examples of malignant human B-lymphoid cell lines include pre-B acute lymphoblastic leukemia (Reh), diffuse large cell lymphoma (WSU-DLCL2), and Waldenstrom's macroglobulinemia (WSU- WM). Unfortunately, many of the existing cell lines do not represent the clinically most common types of leukemia and lymphoma.

The use of Epstein Barr Virus (EBV) infection in vitro has resulted in some CLL derived cell lines, in particular B-CLL cells lines, that are representative of the malignant cells. The phenotype of these cell lines is different than that of the in vivo tumors and instead the features of B-CLL lines tend to be similar to those of Lymphoblastoid cell lines. Attempts to immortalize B-CLL cells with the aid of EBV infection have had little success. The reasons for this are unclear but it is known that it is not due a lack of EBV receptor expression, binding or uptake. Wells et al. found that B-CLL cells were arrested in the G1/S phase of the cell cycle and that transformation associated EBV DNA was not expressed. This suggests that the interaction of EBV with B-CLL cells is different from that with normal B cells. EBV-transformed CLL cell lines moreover appear to differentiate, possessing a morphology more similar to lymphoblastoid cell lines (LCL) immortalized by EBV.

An EBV-negative CLL cell line, WSU-CLL, has been established previously (Mohammad et al., (1996) Leukemia 10(1):130-7). However, no other such cell lines are known.

There remains a need in the art, therefore, for a CLL cell line which has not been established by transformation with EBV, and which expresses surface markers characteristic of primary CLL cells.

## SUMMARY

In one embodiment an CLL cell line of malignant origin is provided that is not established by immortalisation with EBV. The cell line, which was derived from primary CLL cells, and is deposited under ATCC accession no. XXXXX. In a preferred  
5 embodiment, the cell line is CLL-AAT. CLL-AAT is B-CLL cell line, derived from a B-CLL primary cell.

In a further aspect, the CLL-AAT cell line is used to generate monoclonal antibodies useful in the diagnosis and/or treatment of CLL. Antibodies may be generated by using the cells as disclosed herein as immunogens, thus raising an  
10 immune response in animals from which monoclonal antibodies may be isolated. The sequence of such antibodies may be determined and the antibodies or variants thereof produced by recombinant techniques. In this aspect, "variants" includes chimeric, CDR-grafted, humanized and fully human antibodies based on the sequence of the monoclonal antibodies.

Moreover, antibodies derived from recombinant libraries ("phage antibodies")  
15 may be selected using the cells described herein, or polypeptides derived therefrom, as bait to isolate the antibodies on the basis of target specificity.

In a still further aspect, antibodies may be generated by panning antibody libraries using primary CLL cells, or antigens derived therefrom, and further screened  
20 and/or characterized using the cell line of the invention. Accordingly, a method for characterizing an antibody specific for CLL is provided, which includes assessing the binding of the antibody to a CLL cell line.

In a further aspect, there is provided a method for identifying proteins uniquely expressed in CLL cells employing the CLL-AAT cell line, by methods well known to  
25 those, skilled with art, such as by immunoprecipitation followed by mass spectroscopy analyses. Such proteins may be uniquely expressed in the CLL-AAT cell line, or in primary cells derived from CLL patients.

Small molecule libraries (many available commercially) may be screened using the CLL-AAT cell line in a cell-based assay to identify agents capable of modulating  
30 the growth characteristics of the cells. For example, the agents may be identified

which modulate apoptosis in the CLL-AAT cell line, or which inhibit growth and/or proliferation thereof. Such agents are candidates for the development of therapeutic compounds.

5 Nucleic acids isolated from CLL-AAT cell lines may be used in subtractive hybridization experiments to identify CLL-specific genes or in micro array analyses (e.g., gene chip experiments). Genes whose transcription is modulated in CLL cells may be identified. Polypeptide or nucleic acid gene products identified in this manner are useful as leads for the development of antibody or small molecule therapies for CLL.

10 In a preferred aspect, the CLL-AAT cell line may be used to identify internalizing antibodies, which bind to cell surface components which are internalized by the cell. Such antibodies are candidates for therapeutic use. In particular, single-chain antibodies, which remain stable in the cytoplasm and which retain intracellular binding activity, may be screened in this manner.

#### 15 BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. schematically illustrates typical steps involved in cell surface panning of antibody libraries by magnetically-activated cell sorting (MACS).

20 Fig. 2. is a graph showing the results of whole cell ELISA demonstrating binding of selected scFv clones to primary B-CLL cells and absence of binding to normal human PBMC. The designation 2°+3° in this and other figures refers to negative control wells stained with Mouse Anti-HA and detecting antimouse antibodies alone. The designation RSC-S Library in this and other figures refers to soluble antibodies prepared from original rabbit scFv unpanned library. The designation R3/RSC-S Pool in this and other figures refers to soluble antibodies prepared from entire pool of scFv antibodies from round 3 of panning. Anti-CD5 antibody was used as a positive control to verify that equal numbers of B-CLL and PBMC cells were plated in each well.

25 Fig. 3. is a graph showing the results of whole cell ELISA comparing binding of selected scFv antibodies to primary B-CLL cells and normal primary human B cells. Anti-CD19 antibody was used as a positive control to verify that equal numbers of B-

CLL and normal B cells were plated in each well. Other controls were as described in the legend to Fig 2.

Fig. 4. is a graph showing the results of whole cell ELISA used to determine if scFv clones bind to patient-specific (i.e. idiotype) or blood type-specific (i.e. HLA) antigens. Each clone was tested for binding to PBMC isolated from 3 different B-CLL patients. Clones that bound to 1 patient sample were considered to be patient or blood type-specific.

Fig. 5. is a graph showing the results of whole cell ELISA comparing binding of scFv clones to primary B-CLL cells and three human leukemic cell lines. Ramos is a mature B cell line derived from a Burkitt's lymphoma. RL is a mature B cell line derived from a non-Hodgkin's lymphoma. TF-I is an erythroblastoid cell line derived from a erythroleukemia.

Fig. 6. is a graph showing the results of whole cell ELISA comparing binding of scFv clones to primary B-CLL cells and CLL-AAT, a cell line derived from a B-CLL patient. TF-I cells were included as a negative control.

Fig. 7 shows the binding specificity of scFv antibodies in accordance with this disclosure as analyzed by 3-color flow cytometry. In normal peripheral blood mononuclear cells, the antigen recognized by scFv-9 is moderately expressed on B lymphocytes and weakly expressed on a subpopulation of T lymphocytes. PBMC from a normal donor were analyzed by 3-color flow cytometry using anti-CD5-FITC, anti-CD19-PerCP, and scFv-9/Anti-HA-biotin/streptavidin-PE.

Fig. 8 shows the expression levels of antigens recognized by scFv antibodies in accordance with this disclosure.

Fig. 9 is Table 1 which provided a summary of CDR sequences and binding specificities of selected scFv antibodies.

Fig 10. is Table 2 which shows a summary of flow cytometry results comparing expression levels of scFv antigens on primary CLL cells vs. normal PBMC as described in Fig 8.

## DETAILED DESCRIPTION

### Definitions

"CLL", as used herein, refers to chronic lymphocytic leukemia involving any lymphocyte, including but not limited to various developmental stages of B cells and T cells, including but not limited to B cell CLL. B-CLL, as used herein, refers to leukemia  
5 with a mature B cell phenotype which is CD5<sup>+</sup>, CD23<sup>+</sup>, CD20<sup>dim+</sup>, sIg<sup>dim+</sup> and arrested in G0/G1 of the cell cycle.

"Malignant origin" refers to the derivation of the cell line from malignant CLL primary cells, as opposed to non-proliferating cells which are transformed, for  
10 example, with EBV. Cell lines according to this disclosure may be themselves malignant in phenotype, or not. A CLL cell having a "malignant" phenotype encompasses cell growth unattached from substrate media characterized by repeated cycles of cell growth and exhibits resistance to apoptosis.

### Preparation of Cell Lines

15 Cell lines may be produced according to established methodologies known to those skilled in the art. In general, cell lines are produced by culturing primary cells derived from a patient until immortalized cells are spontaneously generated in culture. These cells are then isolated and further cultured, to produce clonal cell populations or cells exhibiting resistance to apoptosis.

20 For example, CLL cells may be isolated from peripheral blood drawn from a patient suffering from CLL. The cells may be washed, and optionally immunotyped in order to determine the type(s) of cells present. Subsequently, the cells may be cultured in a medium, such as a medium containing IL-4. Advantageously, all or part of the medium is replaced one or more times during the culture process. Cell lines may  
25 be isolated thereby, and will be identified by increased growth in culture.

### Preparation of Monoclonal Antibodies

Antibodies, as used herein, refers to complete antibodies or antibody fragments capable of binding to a selected target. Included are Fv, ScFv, Fab' and F(ab')<sub>2</sub>.

monoclonal and polyclonal antibodies, engineered antibodies (including chimeric, CDR-grafted and humanized, fully human antibodies, and artificially selected antibodies), and synthetic or semi synthetic antibodies produced using phage display or alternative techniques. Small fragments, such as Fv and ScFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution.

The antibodies are especially indicated for diagnostic and therapeutic applications. Accordingly, they may be altered antibodies comprising an effector protein such as a toxin or a label. Especially preferred are labels which allow the imaging of the distribution of the antibody in vivo. Such labels may be radioactive labels or radiopaque labels, such as metal particles, which are readily visualisable within the body of a patient. Moreover, the labels may be fluorescent labels or other labels which are visualisable on tissue samples removed from patients.

Recombinant DNA technology may be used to improve the antibodies produced in accordance with this disclosure. Thus, chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimized by humanizing the antibodies by CDR grafting and, optionally, framework modification. See, U.S. Patent No. 5,225,539, the contents of which are incorporated herein by reference.

Antibodies may be obtained from animal serum, or, in the case of monoclonal antibodies or fragments thereof produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

In another embodiment, a process for the production of an antibody disclosed herein includes culturing a host, e.g. E. coli or a mammalian cell, which has been transformed with a hybrid vector. The vector includes one or more expression cassettes containing a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding the antibody protein. The antibody protein is then collected and isolated. Optionally,



intraperitoneally into Balb/c mice optionally pre-treated with pristine. After one to two weeks, ascitic fluid is taken from the animals.

The foregoing, and other, techniques are discussed in, for example, Kohler and Milstein, (1975) Nature 256:495-497; U.S. Patent No. 4,376,110; Harlow and Lane, 5 Antibodies: a Laboratory Manual, (1988) Cold Spring Harbor, the disclosures of which are all incorporated herein by reference. Techniques for the preparation of recombinant antibody molecules is described in the above references and also in, for example WO97/08320; U.S. Patent No. 5,427,908; U.S. Patent No. 5,508,717; Smith, 1985, Science, Vol. 225, pp 1315-1317; Parmley and Smith 1988, Gene 73, pp 305- 10 318; De La Cruz et al, 1988, Journal of Biological Chemistry, 263 pp 4318-4322; U.S. Patent No. 5,403,484; U.S. Patent No. 5,223,409; WO88/06630; WO92/15679; U.S. Patent No. 5,780,279; U.S. Patent No. 5,571,698; U.S. Patent No. 6,040,136; Davis et al., Cancer Metastasis Rev., 1999; 18(4):421-5; Taylor, et al., Nucleic Acids Research 20 (1992): 6287-6295; Tomizuka et al., Proc. Nat. Academy of Sciences USA 97(2) 15 (2000): 722-727. The contents of all these references are incorporated herein by reference.

The cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of CLL cells, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay. 20 For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulfate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel filtration, ion- 25 exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography, e.g. affinity chromatography with a one or more surface polypeptides derived from a CLL cell line according to this disclosure, or with Protein-A or G.

Another embodiment provides a process for the preparation of a bacterial cell 30 line secreting antibodies directed against the cell line characterized in that a suitable

the expression cassette may include a promoter operably linked to polycistronic, for example bicistronic, DNA sequences encoding antibody proteins each individually operably linked to a signal peptide in the proper reading frame.

Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which include the customary standard culture media (such as, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium), optionally replenished by a mammalian serum (e.g. fetal calf serum), or trace elements and growth sustaining supplements (e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like). Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art. For example, for bacteria suitable culture media include medium LE, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9 Minimal Medium. For yeast, suitable culture media include medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

In vitro production provides relatively pure antibody preparations and allows scale-up to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast, plant, or mammalian cell cultivation are known in the art and include homogeneous suspension culture (e.g. in an airlift reactor or in a continuous stirrer reactor), and immobilized or entrapped cell culture (e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges).

Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells in vivo. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected

mammal, for example a rabbit, is immunized with pooled CLL patient samples. A phage display library produced from the immunized rabbit is constructed and panned for the desired antibodies in accordance with methods well known in the art (such as, for example, the methods disclosed in the various references incorporated herein by reference).

Hybridoma cells secreting the monoclonal antibodies are also contemplated. The preferred hybridoma cells are genetically stable, secrete monoclonal antibodies described herein of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.

In another embodiment, a process is provided for the preparation of a hybridoma cell line secreting monoclonal antibodies directed to the CLL cell line is described herein. In that process, a suitable mammal, for example a Balb/c mouse, is immunized with a one or more polypeptides or antigenic fragments thereof derived from a cell described in this disclosure, the cell line itself, or an antigenic carrier containing a purified polypeptide as described. Antibody-producing cells of the immunized mammal are grown briefly in culture or fused with cells of a suitable myeloma cell line. The hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example, spleen cells of Balb/c mice immunized with the cell line of the invention are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag 14, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are cloned.

Preferred is a process for the preparation of a hybridoma cell line, characterized in that Balb/c mice are immunized by injecting subcutaneously and/or intraperitoneally between  $10^6$  and  $10^7$  cells of a cell line in accordance with this disclosure several times, e.g. four to six times, over several months, e.g. between two and four months. Spleen cells from the immunized mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably, the myeloma cells are fused with a three- to twenty-fold excess of spleen cells from the immunized mice in a solution containing

about 30% to about 50% polyethylene glycol of a molecular weight around 4000. After the fusion, the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma  
5 cells.

In a further embodiment, recombinant DNA comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to the cell line described hereinbefore are produced. The term DNA includes coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs  
10 and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

Furthermore, DNA encoding a heavy chain variable domain and/or a light chain variable domain of antibodies directed to the cell line disclosed herein can be enzymatically or chemically synthesized DNA having the authentic DNA sequence  
15 coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted or exchanged with one or more other amino acids. Preferably said modification(s) are outside the CDRs of the  
20 heavy chain variable domain and/or of the light chain variable domain of the antibody in humanization and expression optimization applications. The term mutant DNA also embraces silent mutants wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). The term mutant sequence also includes a degenerated sequence. Degenerated sequences are  
25 degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly E. coli, to obtain an optimal expression of  
30 the heavy chain murine variable domain and/or a light chain murine variable domain.

The term mutant is intended to include a DNA mutant obtained by in vitro mutagenesis of the authentic DNA according to methods known in the art.

For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

Recombinant DNAs including an insert coding for a heavy chain murine variable domain of an antibody directed to the cell line disclosed herein fused to a human constant domain  $\gamma$ , for example  $\gamma 1$ ,  $\gamma 2$ ,  $\gamma 3$  or  $\gamma 4$ , preferably  $\gamma 1$  or  $\gamma 4$  are also provided. Recombinant DNAs including an insert coding for a light chain murine variable domain of an antibody directed to the cell line disclosed herein fused to a human constant domain  $\kappa$  or  $\lambda$ , preferably  $\kappa$  are also provided

Another embodiment pertains to recombinant DNAs coding for a recombinant polypeptide wherein the heavy chain variable domain and the light chain variable domain are linked by way of a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA coding for a peptide facilitating the purification of the antibody and/or a cleavage site and/or a peptide spacer and/or an effector molecule.

The DNA coding for an effector molecule is intended to be a DNA coding for the effector molecules useful in diagnostic or therapeutic applications. Thus, effector molecules which are toxins or enzymes, especially enzymes capable of catalyzing the activation of prodrugs, are particularly indicated. The DNA encoding such an effector molecule has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.

Antibodies and antibody fragments disclosed herein are useful in diagnosis and therapy. Accordingly, a composition for therapy or diagnosis comprising an antibody disclosed herein is provided.

In the case of a diagnostic composition, the antibody is preferably provided together with means for detecting the antibody, which may be enzymatic, fluorescent,

radioisotopic or other means. The antibody and the detection means may be provided for simultaneous, separate or sequential use, in a diagnostic kit intended for diagnosis.

#### Uses of the Cell Line of the Invention

There are many advantages to the development of a CLL cell line, as it  
5 provides an important tool for the development of diagnostics and treatments for CLL.

A cell line according to this disclosure may be used for in vitro studies on the etiology, pathogenesis and biology of CLL. This assists in the identification of suitable agents that are useful in the therapy of CLL disease.

The cell line may also be used to produce monoclonal antibodies for in vitro and  
10 in vivo diagnosis of CLL, as referred to above, and for the screening and/or characterization of antibodies produced by other methods, such as by panning antibody libraries with primary cells and/or antigens derived from CLL patients.

The cell line may be used as such, or antigens may be derived therefrom. Advantageously, such antigens are cell-surface antigens specific for CLL. They may  
15 be isolated directly from cell lines according to this disclosure. Alternatively, a cDNA expression library made from a cell line described herein may be used to express CLL-specific antigens, useful for the selection and characterization of anti-CLL antibodies and the identification of novel CLL-specific antigens.

Treatment of CLL using monoclonal antibody therapy has been proposed in the  
20 art. Recently, Hainsworth (Oncologist 5 (5) (2000) 376-384) has described the current therapies derived from monoclonal antibodies. Lymphocytic leukemia in particular is considered to be a good candidate for this therapeutic approach due to the presence of multiple lymphocyte-specific antigens on lymphocyte tumors.

Existing antibody therapies (such as Rituximab<sup>TM</sup>, directed against the CD20-  
25 antigen, which is expressed on the surface of B-lymphocytes) have been used successfully against certain lymphocytic disease. However, a lower density CD20 antigen is expressed on the surface of B-lymphocytes in CLL (Almasri et al., Am. J. Hematol., 40 (4) (1992) 259-263).

The CLL cell line described herein thus permits the development of novel anti-CLL antibodies having specificity for one or more antigenic determinants of the cell line of the invention, and their use in the therapy and diagnosis of CLL.

In order that those skilled in the art may be better able to practice the  
5 compositions and methods described herein, the following examples are given for illustration purposes.

### **EXAMPLE 1**

#### **Isolation of Cell Line CLL-AAT**

##### *Establishment of the cell line*

Peripheral blood from a patient diagnosed with CLL was obtained. The WBC  
10 count was  $1.6 \times 10^8$ /ml. Mononuclear cells were isolated by Histopaque-1077 density gradient centrifugation (Sigma Diagnostics, St. Louis, MO). Cells were washed twice with Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), and resuspended in 5 ml of ice-cold IMDM/10% FBS. Viable cells were counted by staining with trypan blue. Cells were mixed with an  
15 equal volume of 85% FBS/15% DMSO and frozen in 1 ml aliquots for storage in liquid nitrogen.

Immunophenotyping showed that >90% of the CD45+ lymphocyte population expressed IgD, kappa light chain, CD5, CD19, and CD23. This population also expressed low levels of IgM and CD20. Approximately 50% of the cells expressed  
20 high levels of CD38. The cells were negative for lambda light chain, CD10 and CD138

An aliquot of the cells was thawed, washed, and resuspended at a density of  $10^7$ /mL in IMDM supplemented with 20% heat-inactivated FBS, 2mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-mercaptoethanol, and 5 ng/ml recombinant human IL-4 (R & D Systems, Minneapolis, MN). The cells were cultured  
25 at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. The medium was partially replaced every 4 days until steady growth was observed. After 5 weeks, the number of cells in the culture began to double approximately every 4 days. This cell line was designated CLL-AAT.

### *Characterization of the cell line*

Immunophenotyping of the cell line by flow cytometry showed high expression of IgM, kappa light chain, CD23, CD38, and CD138, moderate expression of CD19 and CD20, and weak expression of IgD and CD5. The cell line was negative for lambda light chain, CD4, CD8, and CD10.

- 5 Immunophenotyping of the cell line was also done by whole cell ELISA using a panel of rabbit scFv antibodies that had been selected for specific binding to primary B-CLL cells. All of these CLL-specific scFv antibodies also recognized the AAT-CLL cell line. In contrast, the majority of the scFvs did not bind to two cell lines derived from B cell lymphomas: Ramos, a Burkitt's lymphoma cell line, and RL, a non-  
10 Hodgkin's lymphoma cell line.

### **Example 2**

#### Selection of scFv Antibodies for B-CLL-specific Cell Surface Antigens using Antibody Phage Display and Cell Surface Panning

##### *Immunizations and scFv antibody library construction*

- Peripheral blood mononuclear cells (PBMC) were isolated from blood drawn from CLL patients at the Scripps Clinic (La Jolla, CA). Two rabbits were immunized with  $2 \times 10^7$  PBMC pooled from 10 different donors with CLL. Three immunizations, two  
15 sub-cutaneous injections followed by one intravenous injection, were done at three week intervals. Serum titers were checked by measuring binding of serum IgG to primary CLL cells using flow cytometry. Five days after the final immunization, spleen, bone marrow, and PBMC were harvested from the animals. Total RNA was isolated from these tissues using Tri-Reagent (Molecular Research Center, Inc). Single-chain  
20 Fv (scFv) antibody phage display libraries were constructed as previously described (Barbas et al., (2001) Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). For cell surface panning, phagemid particles from the reamplified library were precipitated with polyethylene



glycol (PEG), resuspended in phosphate-buffered saline(PBS) containing 1% bovine serum albumin (BSA), and dialysed overnight against PBS.

*Antibody selection by cell surface panning*

The libraries were enriched for CLL cell surface-specific antibodies by positive-negative selection with a magnetically-activated cell sorter (MACS) as described by Siegel et al.(1997, J. Immunol. Methods 206:73-85). Briefly, phagemid particles from the scFv antibody library were preincubated in MPBS (2% nonfat dry milk, 0.02% sodium azide in PBS, pH 7.4) for 1 hour at 25°C to block nonspecific binding sites. Approximately  $10^7$  primary CLL cells were labeled with mouse anti-CD5 IgG and mouse anti-CD19 IgG conjugated to paramagnetic microbeads (Miltenyi Biotec, Sunnyvale, CA). Unbound microbeads were removed by washing. The labeled CLL cells ("target cells") were mixed with an excess of "antigen-negative absorber cells", pelleted, and resuspended in 50 $\mu$ l ( $10^{10}$ - $10^{11}$  cfu) of phage particles. The absorber cells serve to soak up phage that stick non-specifically to cell surfaces as well as phage specific for "common" antigens present on both the target and absorber cells. The absorber cells used were either TF-1 cells (a human erythroleukemia cell line) or normal human B cells isolated from peripheral blood by immunomagnetic negative selection (StemSep system, StemCell Technologies, Vancouver, Canada). The ratio of absorber cells to target cells was approximately 10 fold by volume. After a 30 minute incubation at 25°C, the cell/phage mixture was transferred to a MiniMACS MS<sup>+</sup> separation column. The column was washed twice with 0.5 ml of MPBS, and once with 0.5 ml of PBS to remove the unbound phage and absorber cells. The target cells were eluted from the column in 1 ml of PBS and pelleted in a microcentrifuge at maximum speed for 15 seconds. The captured phage particles were eluted by resuspending the target cells in 200  $\mu$ l of acid elution buffer (0.1 N HCl, pH adjusted to 2.2 with glycine, plus 1  $\mu$ g/ml BSA). After a 10 minute incubation at 25°C, the buffer was neutralized with 12  $\mu$ L of 2M Tris base, pH10.5, and the eluted phage were amplified in *E. coli* for the next round of panning. For each round of panning, the input and output phage titers were determined. The input titer is the number of reamplified phage particles added to the target cell/absorber cell mixture and the output titer is the

number of captured phage eluted from the target cells. An enrichment factor (E) is calculated using the formula  $E = (R_n \text{ output} / R_n \text{ input}) / (R_1 \text{ output} / R_1 \text{ input})$ . In most cases, an enrichment factor of  $10^2$ - $10^3$  fold should be attained by the third or fourth round.

*Analysis of enriched antibody pools following panning*

- 5        After 3-5 rounds of panning, the pools of captured phage were assayed for binding to CLL cells by flow cytometry and/or whole cell ELISA:
  1. To produce an entire pool in the form of HA-tagged soluble antibodies, 2ml of a non-suppressor strain of E. coli (e.g. TOP10F') was infected with 1 $\mu$ l ( $10^9$ - $10^{10}$  cfu) of phagemid particles. The original, unpanned library was used as a negative  
10       control. Carbenicillin was added to a final concentration of 20 $\mu$ M and the culture was incubated at 37°C with shaking at 250rpm for 1 hour. Eight ml of SB medium containing 50 $\mu$ g/ml carbenicillin was added and the culture was grown to an OD 600 of ~0.8. IPTG was added to a final concentration of 1mM to induce scFv expression from the Lac promoter and shaking at 37°C was continued for 4 hours.  
15       The culture was centrifuged at 3000xg for 15'. The supernatant containing the soluble antibodies was filtered and stored in 1 ml aliquots at -20°C.
  2. Binding of the scFv antibody pools to target cells vs. absorber cells was determined by flow cytometry using high-affinity Rat Anti-HA (clone 3F10, Roche Molecular Biochemicals) as secondary antibody and PE-conjugated Donkey Anti-Rat as  
20       tertiary antibody.
  3. Binding of the antibody pools to target cells vs. absorber cells was also determined by whole-cell ELISA as described below.

*Screening individual scFv clones following panning*

- To screen individual scFv clones following panning, TOP10F' cells were infected with phage pools as described above, spread onto LB plates containing  
25       carbenicillin and tetracycline, and incubated overnight at 37°C. Individual colonies were inoculated into deep 96-well plates containing 0.6-1.0 ml of SB-carbenicillin

medium per well. The cultures were grown for 6-8 hours in a HiGro shaking incubator (GeneMachines, San Carlos, CA) at 520 rpm and 37°C. At this point, a 90 µl aliquot from each well was transferred to a deep 96-well plate containing 10 µL of DMSO. This replica plate was stored at -80°C. IPTG was added to the original plate to a final  
5 concentration of 1 mM and shaking was continued for 3 hours. The plates were centrifuged at 3000xg for 15 minutes. The supernatants containing soluble scFv antibodies were transferred to another deep 96-well plate and stored at -20°C.

A sensitive whole-cell ELISA method for screening HA-tagged scFv antibodies was developed:

- 10 1. An ELISA plate is coated with concanavalin A (10mg/ml in 0.1 M NaHCO<sub>3</sub>, pH8.6, 0.1 mM CaCl<sub>2</sub>).
2. After washing the plate with PBS, 0.5-1x10<sup>5</sup> target cells or absorber cells in 50µl of PBS are added to each well, and the plate is centrifuged at 250xg for 10 minutes.
3. 50µl of 0.02% glutaraldehyde in PBS are added and the cells are fixed overnight at  
15 4°C.
4. After washing with PBS, non-specific binding sites are blocked with PBS containing 4% non-fat dry milk for 3 hours at room temperature.
5. The cells are incubated with 50µl of soluble, HA-tagged scFv or Fab antibody  
(TOP10F' supernatant) for 2 hours at room temperature, then washed six times  
20 with PBS.
6. Bound antibodies are detected using a Mouse Anti-HA secondary antibody (clone 12CA5) and an alkaline phosphatase (AP)-conjugated Anti-Mouse IgG tertiary antibody. Color is developed with the alkaline phosphatase substrate PNPP and measured at 405nm using a microplate reader.

25 Primary screening of the scFv clones was done by ELISA on primary CLL cells versus normal human PBMC. Clones which were positive on CLL cells and negative

on normal PBMC were rescreened by ELISA on normal human B cells, human B cell lines, TF-1 cells, and the CLL-AAT cell line. The clones were also rescreened by ELISA on CLL cells isolated from three different patients to eliminate clones that recognized patient-specific or blood type-specific antigens. Results from  
5 representative ELISAs are shown in Figures 2-6 and summarized in Table 1.

The number of unique scFv antibody clones obtained was determined by DNA fingerprinting and sequencing. The scFv DNA inserts were amplified from the plasmids by PCR and digested with the restriction enzyme BstNI. The resulting fragments were separated on a 4% agarose gel and stained with ethidium bromide.  
10 Clones with different restriction fragment patterns must have different amino acid sequences. Clones with identical patterns probably have similar or identical sequences. Clones with unique BstNI fingerprints were further analyzed by DNA sequencing. Twenty-five different sequences were found, which could be clustered into 16 groups of antibodies with closely related complementarity determining regions  
15 (Table 1).

#### *Characterization of scFv antibodies by flow cytometry*

The binding specificities of several scFv antibodies were analyzed by 3-color flow cytometry. PBMC isolated from normal donors were stained with FITC-conjugated anti-CD5 and PerCP-conjugated anti-CD19. Staining with scFv antibody  
20 was done using biotin-conjugated anti-HA as secondary antibody and PE-conjugated streptavidin. Three antibodies, scFv-2, scFv-3, and scFv-6, were found to specifically recognize the CD19<sup>+</sup> B lymphocyte population (data not shown). The fourth antibody, scFv-9, recognized two distinct cell populations: the CD19<sup>+</sup> B lymphocytes and a subset of CD5<sup>+</sup> T lymphocytes (See, Fig 7). Further characterization of the T cell  
25 subset showed that it was a subpopulation of the CD4<sup>+</sup>CD8<sup>-</sup> T<sub>H</sub> cells.

To determine if the antigens recognized by the scFv antibodies were overexpressed on primary CLL cells, PBMC from five CLL patients and five normal donors were stained with scFv and compared by flow cytometry (Fig 8 and Table 2).

By comparing the mean fluorescent intensities of the positive cell populations, the relative expression level of an antigen on CLL cells vs. normal cells could be determined. One antibody, scFv-2, consistently stained CLL cells less intensely than normal PBMC, whereas scFv-3 and scFv-6 both consistently stained CLL cells more brightly than normal PBMC. The fourth antibody, scFv-9, stained two of the five CLL samples much more intensely than normal PBMC, but gave only moderately brighter staining for the other three CLL samples (Fig 8 and Table 2). As seen in Fig 8., the antigens recognized by scFv-3 and scFv-9 are overexpressed on the primary CLL tumor from which the CLL-AAT cell line was derived. Primary PBMC from the CLL patient used to establish the CLL-AAT cell line or PBMC from a normal donor were stained with scFv antibody and analyzed by flow cytometry. ScFv-3 and scFv-9 stain the CLL cells more brightly than the normal PBMC as measured by the mean fluorescent intensities.

This indicates that the antigens for scFv-3 and scFv-6 are overexpressed approximately 2-fold on most if not all CLL tumors, whereas scFv-9 is overexpressed 3 to 6-fold on a subset of CLL tumors.

*Identification of antigens recognized by scFv antibodies by immunoprecipitation (IP) and mass spectrometry (MS)*

To identify the antigens for these antibodies, scFvs were used to immunoprecipitate the antigens from whole cell lysates or lysates prepared from microsomal fractions of cells. The immunoprecipitated antigens were purified by SDS-PAGE and identified by MALDI-MS analysis (data not shown). ScFv-2 immunoprecipitated a 110 kd antigen from both RL and CLL-AAT cells. This was identified as the B cell-specific marker CD19. ScFv-3 and scFv-6 both immunoprecipitated a 45 kd antigen from CLL-AAT cells. This was identified as CD23, which is a known marker for CLL and activated B cells. ScFv-9 immunoprecipitated a 50 kd antigen from CLL-AAT cells. However, we have not yet isolated this antigen in sufficient quantities for MALDI-MS analysis, because its expression appears to have been downregulated on the CLL-AAT cell line.

REFERENCES

The following references are incorporated herein by reference to more fully describe the state of the art to which the present invention pertains. Any inconsistency between these publications below or those incorporated by reference above and the  
5 present disclosure shall be resolved in favor of the present disclosure.

- Almasri, NM et al. (1992). Am J Hemato 140 259-263.  
10 Hainsworth, JD (2000). Oncologist 2000;5(5):376-84  
Nilsson, K (1992). Burn Cell. 5(1):25-41.  
Pu, QQ and Bezwoda, W (2000). Anticancer Res. 20(4):2569- 78.  
10 Walls A Vet al. (1989). Int. J Cancer 44 846-853.

It will be understood that various modifications may be made to the embodiments disclosed herein. Those skilled in the art will envision other modifications within the scope of the claims appended hereto.

We claim:

- 1 1. The cell line CLL-AAT, deposited under ATCC Accession No. XXXXX.
- 1 2. A method for preparing an antibody, comprising the steps of:  
2 (i) generating an antibody to at least one antigen presented on the surface of a  
3 CLL cell line according to claim 1; and  
4 (ii) determining that said antibody binds with an antigen associated with CLL  
5 cells.
- 1 3. A method as in claim 2 wherein the step of determining comprises  
2 determining that said antibody binds with an antigen that is upregulated on CLL cells.
- 1 4. A method as in claim 2 wherein the step of determining comprises  
2 determining that said antibody binds with an antigen specific for CLL cells.
- 1 5. A method according to claim 2, wherein the antibody is generated by  
2 immunization of an organism with a CLL cell line cell, or part thereof, according to  
3 claim 1.
- 1 6. A method according to claim 5, wherein the antibody is generated by  
2 panning a synthetic antibody library with a CLL cell line according to claim 1.
- 1 7. A method according to claim 6, wherein the library is screened by phage  
2 display to isolate the antibody.
- 1 8. A method for characterizing an antibody that binds to CLL cells,  
2 comprising assessing the binding of the antibody to a cell line according to claim 1.

1           9.     A method according to claim 8, wherein the antibody is isolated by  
2 panning an antibody library with primary CLL cells isolated from one or more a patients  
3 suffering from CLL.

1           10.    An antibody produced by the method of claim 2.


1           11.    An antibody that bonds to an antigen that is upregulated by the cell line  
2 of claim 1.

1           12.    An antibody having a sequence selected from the group consisting of  
2 SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5,  
3 SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10,  
4 SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO:  
5 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID.  
6 NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and  
7 SEQ. ID. NO: 25.



1/11

Figure 1



2/11

Fig 2. CELL ELISA





Fig 3. CELL ELISA



4/11

Fig 4. CELL ELISA






Fig 5. CELL ELISA



6/11



Fig 6. CELL ELISA



7/11

Figure 7

FL2: scFv-9/HA-biotin/SA-PE  
 FL1: CD5-FITC  
 FL3: CD19-PerCP





File: PBMC.015

X Parameter: FL1-H FL1-Height (Log)

Y Parameter: FL2-H FL2-Height (Log)

Quad	Events	% Gated	% Total	X Geo Mean	Y Geo Mean
UL	1881	9.40	5.84	6.45	118.74
UR	4368	21.84	13.56	266.89	45.49
LL	2831	14.16	8.79	6.65	7.40
LR	10920	54.60	33.90	282.52	5.72



File: PBMC.015

X Parameter: FL1-H FL1-Height (Log)

Y Parameter: FL3-H FL3-Height (Log)

Quad	Events	% Gated	% Total	X Geo Mean	Y Geo Mean
UL	1874	9.37	5.82	6.55	65.56
UR	409	2.04	1.27	50.57	55.81
LL	2838	14.19	8.81	6.57	4.19
LR	14879	74.39	46.19	291.30	2.17

File: PBMC.015




X Parameter: FL2-H FL2-Height (Log)

Y Parameter: FL3-H FL3-Height (Log)

Quad	Events	% Gated	% Total	X Geo Mean	Y Geo Mean
UL	171	0.85	0.53	10.16	54.88
UR	2112	10.56	6.56	137.20	64.47
LL	13744	68.72	42.67	6.08	2.52
LR	3973	19.86	12.33	41.31	2.08

8/11

Figure 8



\* Numerator Histogram \*  
File: CLL008

\* Denominator Histogram \*  
File: CLL004


Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	9222	99.94	99.94	854.78	553.08	47.14	520.42	80
M1	28	9910	10328	97.84	64.79	887.84	600.89	44.09	628.43	80

\* Numerator Histogram \*  
File: PBMC.008

\* Denominator Histogram \*  
File: PBMC.006

Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	2650	98.68	64.49	1119.7	1318	282.03	818	1
M1	28	9910	2403	11.43	7.83	891.87	708.77	45.81	877.89	1000

Key	Name	Parameter	Gate
---	CLL004	FL2-H	G3
---	CLL008	FL2-H	G3
---	PBMC.008	FL2-H	G1
---	PBMC.006	FL2-H	G1



\* Numerator Histogram \*  
File: PBMC.010

\* Denominator Histogram \*  
File: PBMC.008


Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	2239	103.17	84.94	31.81	8.94	351.33	1.35	1
M1	28	9910	1953	9.89	6.22	281.88	178.73	103.09	201.89	271

\* Numerator Histogram \*  
File: CLL008

\* Denominator Histogram \*  
File: CLL004

Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	1024	99.98	80.73	817.42	345.38	104.91	302.42	385
M1	28	9910	9798	95.37	62.78	614.67	420.58	100.48	414.18	385

Key	Name	Parameter	Gate
---	CLL.004	FL2-H	G1
---	CLL.008	FL2-H	G3
---	PBMC.008	FL2-H	G1
---	PBMC.010	FL2-H	G1



\* Numerator Histogram \*  
File: CLL.018

\* Denominator Histogram \*  
File: CLL.004

Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	10378	103.02	88.65	658.19	431.42	41.37	529.03	528
M1	28	9910	10372	98.08	85.17	679.08	618.00	45.10	532.80	528
M2	103	9910	9028	80.83	63.91	587.05	524.83	44.25	527.61	528

\* Numerator Histogram \*  
File: PBMC.014

\* Denominator Histogram \*  
File: PBMC.008

Marker	Left	Right	Events	% Outd	% Total	Mean	Geo Mean	CV	Median	Peak Ch
AJ	1	9910	30228	100.19	84.62	34.38	15.09	172.49	12.39	1
M1	28	9910	6228	35.74	16.00	600.87	60.28	82.38	71.05	38
M2	103	9910	1803	9.32	6.01	650.40	179.03	45.79	177.83	108

Key	Name	Parameter	Gate
---	CLL.004	FL2-H	G3
---	CLL.018	FL2-H	G3
---	PBMC.008	FL2-H	G1
---	PBMC.014	FL2-H	G1



9/11

Table 1. Summary of CLL scFv Clones.

Pool	Clone	CLL	Primary B	CLL-AAT	RL (NHL)	Ramos (Burkitt's)	TF1	Patient-Specific	Expression Lost	Finger-print
R3/RSC-S CLL-TF1	E1	++	++	++	-	-	-			1
	E2	++	-	++	-	-	-			2
	E3	++	+	++	±	±	±			3
	E4	++	+	++	-	-	-			4
	E11	++	+	++	-	-	-			5
	F1	+	+	+	-	-	-			6
	F2	++	+	++	-	-	-			7
	F12	++	+	++	-	-	-			8
	H6.1	++	+	++	+	+	+			9
	H12	++	+	++	-	-	-			10
	A2	++	++	++	+	+	-			11
	A9	++	+	++	-	-	-			12
	G5.1	-	-	nd	nd	nd	nd	+		13
	G7	-	-	nd	nd	nd	nd	+		14
	G7.1	+	+	+	+	+	+			15
	D3.1	+	+	nd	nd	nd	nd	+		16
	D11.1	++	+	++	-	-	-			17
	G10.1	+	+	+	-	-	-			18
	H6.2	++	++	++	-	-	-			19
	A3.1	++	+	++	-	-	-			20
	A5.2	++	+	++	-	-	-			9
	B3.4	+	+	+	-	-	-			21
	D2.1	+	+	+	-	-	-			22
	D5.1	+	+	+	±	±	±			23
	E3	+	+	+	-	-	-			24
	E4.2	+	+	+	-	-	-			25
	G2.2	-	-	nd	nd	nd	nd	+		26
	H1	-	-	nd	nd	nd	nd	+		27
	H6.3	-	-	nd	nd	nd	nd	+		28
	A3	-	+	+	nd	nd	nd	+		29
R3/RSC-L CLL-TF1	B12.1	+	+	++	nd	nd	nd			30
	C12	++	+	++	+	+	±			31
	D1.1	+	+	+	nd	nd	nd			32
	D5.2	-	-	+	nd	nd	nd	+		33
	D8.2	++	+	++	+	+	±			34
	F10	++	+	++	+	+	±			(nd)
	A1.1	+	+	++	nd	nd	nd			(nd)
	G9	±?	+	++	nd	nd	nd	+		35
	B1	+	+	+	nd	nd	nd			36
	B4.2	++	+	++	nd	nd	nd			37
R5/RSC-L CLL-B	C10	++	+	++	nd	nd	nd			38
	D4.2	-	-	-	nd	nd	nd	+		39
	D11.2	±?	-	+	nd	nd	nd	+		37
	G1.2	++	+	++	-	-	-			40
	D2.2	+	+	+	nd	nd	nd			41
	G12.1	+	+	+	+	+	-			42
	A1.2	±?	nd	++	nd	nd	nd	+		43
	A3.2	+	nd	++	+	+	±			44
R4/RSC-S CLL-B	B3.2	-	nd	+	nd	nd	nd	+		45
	B4.3	-	nd	++	nd	nd	nd	+		46
	B12.2	+	nd	++	+	+	±			47
	G4	++	nd	++	-	-	-			48
	H3.2	++	nd	++	-	-	-			46
	F7	+	nd	++	+	+	-			49
	D7.2	++	nd	++	+	+	±			50
	D12	++	nd	++	+	+	+			51
	E5	++	nd	++	+	+	-			52
	E13.3	+	nd	++	+	+	+			53
	E7.2	+	nd	++	+	+	+			54
	F5.2	+	nd	++	+	+	-			








 CLL + Primary B Cells  
 CLL Cells  
 CLL + All B Cells  
 CLL + All B Cells + TF1dim  
 CLL + All B Cells + TF1bright  
 patient-specific or lost expression  
 not fully characterized

FIGURE 9A

10/11

FIGURE 9B

Table 1. CDR Sequences of CLL Specific Rabbit scFv Antibodies

SEQ	CLONE	LC-CDR1	LC-CDR2	LC-CDR3	HC-CDR1	HC-CDR2	HC-CDR3	Expression Pattern:					Ag	Linker
								CDL	B	RL	Ramos	TF-1		
1	A2c	TLSTGYSVGSVYIA	HSEEAHQGS	ATANGSGSFHV	NYMT	LISSNGCA--DYASWAK	DDEGYDDYGDYMGVETL	+	+	++	+	-	CD19	S
2	G12.1c	QASESIRN---YLA	GASNL---ES	QSGDYSA---GLT	SYGLS	YFDPVFGNI--YYATWVD	DRIYVSSVG---YAFNL	+	+	+	+	-	CD19	L
17	B4.2a	QASESIRN---YLA	GASNL---ES	QSGDYSA---GLT	TYGVS	YNDIFGNT--YYATWVN	DRAVASSSG---YXXXX	+	nd	+	+	-	CD23	L
3	E1c	QASESISN---WLA	RASTL---AS	QSGYISA---GLT	SNAMG	LISSSGGT--YYASWAK	DHIAAGKS---YGLDL	++	+	-	-	-	CD23	S
18	F2d	QASESISN---YLA	GASNL---ES	QSGYISA---GLT	TNMG	LISSSGGT--YYASWAK	DHIAAGKS---YGLDL	++	+	-	-	-	CD23	S
4	E5e	QASQNIYS---NLA	LAFTL---AS	QSGDYSSSSSYG	SSDWIC	CIYTGSSSSTWASWAK	RYTDGNG---IFNL	+	+	-	-	-	CD23	S
5	H6.2b	QASQNIYS---NLA	GASNL---ES	QSGYISP---GVT	SDVIS	YIYTDGST--DYASWVN	DAAYAGYGV---IFNL	++	++	-	-	-	CD23	S
19	G10.1	QASESISN---YLA	GASNL---ES	QSGYISG---GAT	SDVIS	YIYTDGST--DYASWVN	DAAYAGYGV---IFNL	+	+	-	-	-	CD23	S
6	D11.1c	QASESISN---YLA	GASNL---ES	QSGYISG---GAT	TYAMG	SIYASRSP--YYASWAK	GDAGSIP---YFNL	++	+	-	-	-	CD23	S
20	A5.2c	LAENNVYQ---AVA	GASNL---ES	Q-GYSSYP-T	TYAMG	SIYASRSP--YYASWAK	GDAGSIP---YFNL	++	+	-	-	-	CD23	S
7	F1d	QASQSVN---LLA	GASNL---ES	AGYKSSST-D-GIA	SNMT	LIIGDNT--YYASWAK	GNV---FSDL	+	+	-	-	-	CD23	S
8	F1e	QASQSVN---LLA	GASNL---ES	AGYKSSST-D-GIA	SNMT	LIIGDNT--YYASWAK	GNV---FSDL	+	+	-	-	-	CD23	S
21	E4.2	LAENNVYQ---TWS	GASNL---ES	QSGYISA---GLT	DFAMS	VYIAGTRGDTYANWAK	GLT---YFNL	++	+	-	-	-	CD23	S
9	E2c	TLSTGYSVGSVYIA	HTDDIKHQGS	ALAHGTESSFHV	SYGNV	VIDPYGST--YYASWVN	GAYSGVPS---YFNL	+	+	-	-	-	CD23	S
A9c		TLSTGYSVGSVYIA	HTDDIKHQGS	ALAHGTESSFHV	SYGNV	VIDPYGST--YYASWVN	GAYSGVPS---YFNL	++	+	-	-	-	CD23	S
10	E11e	LAENNVYQ---GLS	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
11	A1.1	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
12	F5.2	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
22	F10b	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
23	F7a	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
13	F6b	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
24	C12b	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
14	D2.1b	QASQSVN---LLA	GASNL---ES	QSGYISA---GLT	TNAMS	YIYTDGST--YYASWAK	GNV---FSDL	++	+	-	-	-	CD23	S
25	D1.1	QASEDIES---YLA	GASNL---ES	QSNAMSV---GWT	SNAMS	TIYTGTA--YYASWAK	GNT---YFNL	+	+	-	-	-	CD23	S
15	D2.2a	QSSQSIAGA---YLS	LASKL---AS	AAQYSGN---IYT	SSYHIC	CIYTGSGSTYYASWAK	AYIYGGYG---FFDL	nd	nd	nd	nd	nd	CD23	S
16	D2.2b	LAENNVYQ---AVA	GASNL---ES	Q-GYSSYP-T	NYGVN	YIDPVFUST--YYASWVN	EASFYI---GMDL	nd	nd	nd	nd	nd	CD23	S

SEQ: sequence designation

CLONE: designation of representative clone for sequence

LC: Ig light chain

HC: Ig heavy chain

CDR: complementarity determining region

Expression pattern: binding of scFv antibodies to primary human cells and cell lines as determined by whole cell ELISA assay

CDL: chronic lymphocytic leukemias (primary tumors and CLL-AAT cell line)

B: normal, primary human B lymphocytes

RL: non-Hodgkin's lymphoma cell line

Ramos: Burkitt's lymphoma cell line

TF-1: human erythroleukemia cell line

Ag: antigen recognized by scFv antibody (determined by immunoprecipitation and mass spectrometry)

Linker: type of linker sequence between VL and VH regions. S, short linker; L, long linker

11/11

## FIGURE 10

Table 2. Mean fluorescent intensities of B-CLL cells and normal PBMC labeled with scFv antibodies

Donor	<i>Antibody and CLL/PBMC Ratio:</i>							
	scFv-2	ratio	scFv-3	ratio	scFv-6	ratio	scFv-9	ratio
CLL(ML)	590	0.83	398	2.2	284	2.1	511	6.4
PBMC-1	715		181		137		80	
CLL(JR)	311	0.85	207	2.4	nd	nd	117	1.7
PBMC-2	368		87		nd		67	
CLL(HTS)	219	0.69	173	1.6	nd	nd	176	3.6
PBMC-3	317		106		nd		49	
CLL(RE)	305	0.59	360	3	nd	nd	142	1.7
PBMC-4	513		121		nd		81	
CLL(GB)	262	0.47	387	1.8	nd	nd	163	1.5
PBMC-5	563		212		nd		106	

Primary PBMC from five patients diagnosed with CLL and five normal donors were analyzed by flow cytometry. The geometric mean fluorescent intensities were determined for cells stained with four different scFv antibodies. For scFvs that bind to antigens overexpressed on CLL cells, the CLL/PBMC ratio of fluorescent intensities is >1.0.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number  
**WO 02/059280 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 5/08**,  
C07K 16/30, G01N 33/577 // C12N 15/10

(74) Agents: **DELUCA, Peter** et al.; Dilworth & Barrese, LLP,  
333 Earle Ovington Boulevard, Uniondale, NY 11553  
(US).

(21) International Application Number: PCT/US01/47931

(22) International Filing Date:  
10 December 2001 (10.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/254,113 8 December 2000 (08.12.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ALEX-  
ION PHARMACEUTICALS, INC.** [US/US]; 352 Knot-  
ter Drive, Cheshire, CT 06410 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOWDISH,**  
**Katherine, S.** [US/US]; 13754 Boquita Drive, Del Mar,  
CA 92014 (US). **MCWHIRTER, John** [US/US]; 9499  
Questa Pointe, San Diego, CA 92126 (US).

Published:


— with international search report

(88) Date of publication of the international search report:  
10 April 2003

[Continued on next page]

(54) Title: CHRONIC LYMPHOCYTIC LEUKEMIA CELL LINE AND ITS USE FOR PRODUCING AN ANTIBODY

CELL ELISA



(57) Abstract: A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed.



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/47931

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/08 C07K16/30 G01N33/577 //C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	No relevant documents disclosed -----	

☐

Further documents are listed in the continuation of box C.

☐

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the International search

8 November 2002

Date of mailing of the International search report

29/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Döpfer, K-P

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/47931

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-11  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-11

The present application addresses CLL cell lines, antibodies directed towards these cell lines and their uses in diagnosis and therapy of CLL. The applicant failed to submit the ATCC deposition number in due time. Consequently, the claim so lack support and enablement, i.e. the skilled person is not enabled to carry out the invention (Article 5 PCT). Furthermore, due to the lack of identification which renders the claims so unclear (Article 6 PCT) that no search can be carried out with respect to the subject-matter of present claims 1-11 relating to the unidentified cell lines. A search report could only be drawn up for the fragments of antibodies characterised by their amino acid sequences (claim 12).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.